A-TRAIN
- For patients and health care professionals
- For participating companies/list of participating companies
- List of researchers by participating facilities
Study Overview
A-TRAIN (Study ID: NCCH1905, ClinicalTrials.gov registration number: NCT05099978) is an international multicenter prospective study that was started in 2021 by a project for establishing an Asian clinical trial network (ATLAS Project).
Circulating tumor DNA (ctDNA) will be comprehensively analyzed, targeting cancer patients with metastatic and/or recurrent disease in various Asian countries centered in Japan, Malaysia, Thailand, Singapore, Vietnam, and Taiwan.
This study will allow researchers to obtain information on genetic mutations in a minimally invasive manner and in real time, even in patients with little tumor tissue, and to use this information for post-treatment monitoring purposes. In addition, it will also be possible to verify effective drugs and clarify the need for the development of new drugs, etc., bringing great hope for cancer treatment in the future.
Origin of the Name and Logo
A-TRAIN is an abbreviation for “Asian multicenter prospective study of circulating Tumor DNA Sequencing.”
The ribbon in the logo represents DNA, and this signifies the gradual unraveling of genetic information about cancer. Each cohort will use a logo with a different ribbon color.
